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Abstract Patients with diabetes are at higher risk of devel-
oping carotid artery stenosis and resultant stroke. Arachi-
donoyl phospholipids affect plaque inflammation and 
vulnerability, but whether diabetic patients have unique 
carotid artery phospholipidomic profiles is unknown. We 
performed a comprehensive paired analysis of phospholip-
ids in extracranial carotid endarterectomy (CEA) plaques 
of matched diabetic and nondiabetic patients and analyzed 
mass spectrometry-derived profiles of three phospholipids, 
plasmenyl-phosphatidylethanolamine (pPE), phosphatidylser-
ine (PS), and phosphatidylinositol (PI), in maximally (MAX) 
and minimally (MIN) diseased CEA segments. We also mea-
sured levels of arachidonic acid (AA), produced by pPE 
hydrolysis, and choline-ethanolamine phosphotransferase 
1 (CEPT1), responsible for most pPE de novo biosynthesis. 
In paired analysis, MIN CEA segments had higher levels than 
MAX segments of pPE (P < 0.001), PS (P < 0.001), and PI 
(P < 0.03). MIN diabetic plaques contained higher levels 
than MAX diabetic plaques of arachidonoyl pPE38:4 and 
pPE38:5 and CEPT1 was upregulated in diabetic versus non-
diabetic plaques. AA levels were relatively greater in MIN 
versus MAX segments of all CEA segments, and were higher 
in diabetic than nondiabetic plaques.  Our findings suggest 
that arachidonoyl phospholipids are more likely to be abun-
dant in the extracranial carotid artery plaque of diabetic 
rather than nondiabetic patients.—Zayed, M. A., F-F. Hsu, 
B. W. Patterson, Y. Yan, U. Naim, M. Darwesh, G. De Silva, 
C. Yang, and C. F. Semenkovich. Diabetes adversely affects 
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1 (CEPT1) (11). Ether lipids derived from PE, such as plas-
menyl-PE  (pPE),  are  also  synthesized  by CEPT1  and  are 
highly  concentrated  in  vascular  tissue  and  inflammatory 











tions  by  providing  the  first  phospholipidomic  analysis 
between maximally (MAX) and minimally (MIN) diseased 
CEA  segments  in  diabetic  and  nondiabetic  subjects  with 
high-grade carotid artery stenosis.
MATERIALS AND METHODS
Human subjects and tissue processing






removed en bloc  from  the  subject’s  carotid bifurcation,  and 
immediately sectioned into MAX (the segment that is at the level 
of the carotid bifurcation) and MIN diseased segments (the seg-
ment  that  is at  the plaque periphery distal edge  in  the  internal 
carotid artery; Fig. 1A). The CEA plaque segments were indepen-
dently  inspected  to  confirm  that  MAX  diseased  segments  had 
American Heart Association type IV–VIII atherosclerotic plaques, 
and  MIN  diseased  segments  had  American  Heart  Association 
type I–III atherosclerotic plaques (Fig. 1) (18).





nized  with  a  high-speed  rotational  power  tissue  homogenizer 
(Glas-Col, Terre Haute,  IN). Homogenized  samples underwent 
centrifugation (4,697 g for 5 minutes), and the supernatants were 













with  lipid  extraction  buffer  [2:2  (v/v)  chloroform/methanol] 
and the organic phase was collected. Extracts were then dried 
under  nitrogen  and  reconstituted  in  methanol  with  0.25% 
NH4OH (29%) (19).
Electrospray ionization mass spectrometry
Lipid extracts from MAX and MIN diseased samples obtained 
from 17 patients  (10 diabetic  and 7 nondiabetic;  supplemental 





















Phospholipid  structural  assignments  were made  as  previously 
described (20–29), and as summarized in supplemental Tables S2–
S10. Supplemental Figs. S3–S8 provide product-ion spectra  that 
were used  to produce  structural  determinations  for  each phos-
pholipid group.
Mass spectrometry phospholipid data analysis
The mass  spectrometry-derived  lipid mass  spectrum  for each 
sample was averaged over time, and the average background spec-
trum was  subtracted  from  it. The net  sample  spectrum were 
described as a set of signal intensities of the predefined phospho-










tal Table  S5),  22 PE-related  species  [including  11 PEs  (supple-
mental Table S6) and 11 pPEs (supplemental Table S7)], 13 PG 
species  (supplemental  Table  S8),  16  PI  species  (supplemental 
Table S9), and 7 Cer species (supplemental Table S10).












antibody  (Cell  Signaling,  #2118).  Bands  were  quantified  by 
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meablized with  1% Triton/PBS  solution,  and blocked with  1% 
















A nonparametric Mann-Whitney U  test  was  used  to  evaluate 
differences in age, demographics, and medications between dia-
betic and nondiabetic subjects who provided CEA plaque speci-
mens. Mass  spectrometry  descriptive  analysis  was  performed  to 
evaluate heat map relative fold differences in phospholipid mean 
absolute  quantities.  A nonparametric Wilcoxon  two-sample  test 
was used  to  evaluate differences  between phospholipid  groups 
between MAX and MIN diseased segments, as well as diabetic and 














Biochemical  and molecular  analysis  of MAX and MIN 
diseased human CEA plaque segments was performed using 
specimens collected from 49 human subjects (21 diabetic 
and  28  nondiabetic).  Comparative  analysis  of  subject 
demographics and medication profiles revealed no differ-







CEPT1 expression is elevated in diabetic CEA specimens
Our group  recently demonstrated  that  skeletal muscle 










P  <  0.001),  and  even more  staining  in MAX  segments 





  50–60 (%) 18 10 0.42
  61–70 (%) 29 48 0.18
  71–80 (%) 43 33 0.51
  81–90 (%) 11 10 0.94
Demographics
  Gender (n) M28/F8 M21/F8 0.49
  BMI 30 (%) 14 67 <0.001
a
  Current Smoker (%) 11 29 0.11
  Hypertension (%) 79 95 0.10
  Hyperlipidemia (%) 82 90 0.42
  CAD (%) 43 48 0.75
  Stroke (%) 32 29 0.79
Medications
  Antiplatelet (%) 100 76 0.02a
  Beta-blocker (%) 25 76 <0.001a
  Statin (%) 82 81 0.92
  Insulin (%) 0 33 <0.001a
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Content of pPEs and PSs is increased in MIN diseased 
CEA segments
The terminal enzyme of the Kennedy pathway is CEPT1, 













were  observed  in  the  relative  absolute  quantities  of  PC, 
aPC, SM, PE, Cer, or PG groups between MAX and MIN 
segments of diabetic and nondiabetic subjects (Table 2).
Arachidonoyl pPEs are more abundant in MIN diseased 
CEA segments
To determine which  specific pPE and PS  species were 




tities  of  specific  pPEs  (pPE36:4,  pPE38:4,  pPE38:5,  and 
pPE40:7; Fig. 2A) and PSs (PS38:3, PS38:5, PS40:4, PS40:5, 
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AA is more abundant in MIN diseased CEA plaque 
segments
Atherosclerosis  increases  group  IVA  cPLA2  expression 
and  activation  in  the  artery media  (32), which  results  in 
arachidonoyl  phospholipid  hydrolysis  and  the  release  of 




evaluated  cPLA2  protein  abundance  in MAX  and MIN 
segments. We  observed  slightly  higher  cPLA2  in MAX 






Because  the  content  of  both  arachidonoyl  pPEs  and 
cPLA2 levels in CEA plaque appeared to be altered relative 





























PC 0.63 0.75 0.24 0.67 0.97 0.11 0.61 0.59 1
aPC 0.3 0.31 0.85 0.33 0.44 0.3 0.28 0.21 0.28
SM 1.51 1.57 0.68 1.57 2.02 0.38 1.46 1.26 1
PE 0.23 0.24 0.64 0.25 0.23 0.81 0.21 0.24 0.43
pPE 0.3 0.47 0.001a 0.3 0.42 0.11 0.29 0.51 0.01a
PI 0.14 0.19 0.05a 0.14 0.22 0.03a 0.14 0.17 0.56
Cer 0.06 0.05 0.49 0.06 0.07 0.94 0.05 0.03 0.32
PS 0.19 0.44 <0.001a 0.17 0.38 0.03a 0.2 0.5 <0.01a
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more prevalent use of statins and tighter glycemic control, 











segments  have  different  phospholipidomic  profiles.  To 
our knowledge, our group is the first to evaluate the phos-
pholipidomic content and metabolism of variably diseased 
CEA  segments  from matched  human  subjects.  This  is 
highly informative, because the angle, curvature, and width 
across the carotid bifurcation contribute to differential 
intimal  shear  stress  leading  to  heterogeneous  plaque 





account  for  the  known  heterogeneous  nature  of  CEA 
plaques,  and  are  limited by  the  lack of  relatively  “less-
diseased” specimen controls.
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biosynthesis of PCs, PEs, and pPEs. Our findings are  the 
first  to  demonstrate  that  both  CEPT1  protein  and  cept1 
mRNA expression are  significantly  increased  in MIN dis-
eased CEA segments of diabetic subjects. We also observed 
that MIN  diseased  CEA  segments  contained  the  highest 
content of arachidonoyl pPEs (pPE38:4 and pPE38:5). On 
the  other  hand,  MAX  diseased  CEA  segments  demon-
strated  both  lower  CEPT1  expression  and  lower  arachi-
donoyl pPE plaque content. The observed correlations 
between CEPT1 expression and pPE content in MIN and 
MAX diseased CEA  segments  suggests  that CEPT1  is  an 
important mediator of plaque phospholipogenesis. Our 








induced  diabetes  increases  murine  CEPT1  expression, 
and weight loss in obese human subjects decreases CEPT1 
expression (31). Mice with a skeletal muscle CEPT1 de-


























glycated end products  and AA metabolites,  such  as  eiso-
sanoids and prostaglandins (36). Collectively, this is thought 





































strate  altered  PS  membrane  content  in  the  setting  of 
chronic hyperglycemia and diabetes (43, 60, 61). In the set-
ting  of  diabetes,  increased  membrane  PSs  in  red  blood 
cells and endothelial cells are thought to increase cell-cell 
adhesion and promote vessel thrombosis (60). PS synthases 
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in the ER can covert PC, PE, and pPE into PS (8, 9, 58, 62). 
Although  we  did  not  observe  a  correlation  between  the 









CEA  segments,  AA  content  is  also  increased  relative  to 
MAX diseased segments. These findings provide  the first 
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